Abstract: Systems, apparatuses, and methods for implementing a hierarchical scheduler. In various implementations, a processor includes a global scheduler, and a plurality of independent local schedulers with each of the local schedulers coupled to a plurality of processors. In one implementation, the processor is a graphics processing unit and the processors are computation units. The processor further includes a shared cache that is shared by the plurality of local schedulers. Each of the local schedulers also includes a local cache used by the local scheduler and processors coupled to the local scheduler. To schedule work items for execution, the global scheduler is configured to store one or more work items in the shared cache and convey an indication to a first local scheduler of the plurality of local schedulers which causes the first local scheduler to retrieve the one or more work items from the shared cache.

Abstract: Systems, apparatuses, and methods for implementing a message passing system to schedule work in a computing system. In various implementations, a processor includes a global scheduler, and a plurality of local schedulers with each of the local schedulers coupled to a plurality of processors. The processor further includes a shared cache that is shared by the plurality of local schedulers. Also, a plurality of mailboxes are implemented to enable communication between the local schedulers and the global scheduler. To schedule work items for execution, the global scheduler is configured to store one or more work items in the shared cache and store an indication in a mailbox for a first local scheduler of the plurality of local schedulers. Responsive to detecting the message in the mailbox, the first local scheduler identifies a location of the one or more work items in the shared cache and retrieves them for scheduling locally.

Abstract: The invention provides various methods comprising the administration of a CYP2D6 bioactive drug covalently bound to a water-soluble oligomer. Metabolism of CYP2D6 bioactive drug conjugates is diverted from CYP2D6 to alternative pathways, and the conjugates may therefore be utilized to alleviate the problems associated with interpopulation variation resulting from the genetic polymorphism in the CYP2D6 gene.

Abstract: The invention provides various methods comprising the administration of a CYP2D6 bioactive drug covalently bound to a water-soluble oligomer. Metabolism of CYP2D6 bioactive drug conjugates is diverted from CYP2D6 to alternative pathways, and the conjugates may therefore be utilized to alleviate the problems associated with interpopulation variation resulting from the genetic polymorphism in the CYP2D6 gene.

Abstract: Described herein are solid, pharmaceutical compositions, dosage forms and methods of making and using the same, wherein the solid compositions comprise at least one high viscosity agent. The solid, high viscosity agent-comprising pharmaceutical compositions, when comprised of an opioid drug, can reduce the potential for abuse of such drug. The solid dosage forms are characterized by having a significantly reduced extractability of an opioid drug comprised therein upon contact of the dosage form with a solvent such as a typical household solvent. The solid dosage forms, following contact with a household solvent, such as an aqueous or alcoholic solvent, generate a high viscosity solution, thereby discouraging abuse of the resulting formulation via intravenous (IV) injection.

Abstract: Provided herein are compounds and methods for achieving a sustained therapeutic effect of small molecule anti-cancer agents when administered in vivo.

Abstract: Provided is a method of treating an individual suffering from a cancer such as breast cancer by administering to the individual a long-acting topoisomerase I inhibitor, and correlating the level of one or more tumor markers in the individual with response of the cancer to treatment with the long-acting topoisomerase I inhibitor, to thereby provide a method for predicting and assessing the therapeutic efficacy of the treatment.

Abstract: Provided is a method of treating an individual suffering from a cancer such as breast cancer by administering to the individual a long-acting topoisomerase I inhibitor such as SN-38 or irinotecan, and correlating the level of at least one tumor marker such as CA27.29 in the individual with response of the cancer to treatment with the long-acting topoisomerase I inhibitor, to thereby provide a method for predicting and assessing the therapeutic efficacy of the treatment.

Abstract: Provided herein are compounds and methods for achieving a sustained therapeutic effect of small molecule anti-cancer agents when administered in vivo.

Abstract: Among other things, a method of treating a human having brain cancer is, the method comprising administering via a non-continuous dosing regimen to the human having brain cancer, a therapeutically effective amount of a pharmaceutical composition comprising a prodrug or a pharmaceutically acceptable salt thereof, wherein the non-continuous dosing regimen comprises administering the pharmaceutical composition no more frequently than once every seven days for at least two dosings.

Abstract: The inventions provided herein relate to methods, and compositions for increasing neuronal connectivity, neuronal survival and/or axonal growth of a population of neural cells in vitro, ex vivo or in vivo. For in vivo applications, in some embodiments, the methods and compositions described herein can be used to treat cognitive, motor and/or sensory function impairment and/or neurodegeneration in a subject or particularly a human subject {e.g., a human subject who is diagnosed as having, or having a risk, for a neurodegenerative and/or neurological condition such as Alzheimer's disease). Methods for determining a risk for a neurodegenerative condition or disorder, e.g., Alzheimer's disease, in a subject {e.g., a human subject) are also provided herein.

Abstract: Provided is a method of treating an individual suffering from a cancer such as breast cancer by administering to the individual a long-acting topoisomerase I inhibitor such as SN-38 or irinotecan, and correlating the level of at least one tumor marker such as CA27.29 in the individual with response of the cancer to treatment with the long-acting topoisomerase I inhibitor, to thereby provide a method for predicting and assessing the therapeutic efficacy of the treatment.

Abstract: Among other things, a method of treating a human having brain cancer is, the method comprising administering via a non-continuous dosing regimen to the human having brain cancer, a therapeutically effective amount of a pharmaceutical composition comprising a prodrug or a pharmaceutically acceptable salt thereof, wherein the non-continuous dosing regimen comprises administering the pharmaceutical composition no more frequently than once every seven days for at least two dosings.

Abstract: The invention relates to (among other things) a method comprising the steps of (a) administering to a patient a topoisomerase II-inhibiting amount of a long-acting topoisomerase II inhibitor; and (b) administering to the patient a topoisomerase I-inhibiting amount of a long-acting topoisomerase I inhibitor.

Abstract: Provided herein are compounds and methods for achieving a sustained therapeutic effect of small molecule anti-cancer agents when administered in vivo.

Abstract: Aerosolizable formulations comprising: an insulin derivative having an isoelectric point (pI) ranging from about 6 to about 8; and a pharmaceutically acceptable excipient including a precipitating agent.

Abstract: Formulations are provided for pulmonary administration of an antifungal agent to a patient. Methods of using the formulations in the treatment of antifungal infections are also provided, including treatment of pulmonary aspergillosis with amphotericin B-containing formulations. Methods of manufacturing the formulations to achieve optimum properties are provided as well.

Abstract: Provided herein are compounds and methods for achieving a sustained therapeutic effect of small molecule anti-cancer agents when administered in vivo.

Abstract: The invention provides various methods comprising the administration of a CYP2D6 bioactive drug covalently bound to a water-soluble oligomer. Metabolism of CYP2D6 bioactive drug conjugates is diverted from CYP2D6 to alternative pathways, and the conjugates may therefore be utilized to alleviate the problems associated with interpopulation variation resulting from the genetic polymorphism in the CYP2D6 gene.

Abstract: Aerosolizable formulations comprising: an insulin derivative having an isoelectric point (pI) ranging from about 6 to about 8; and a pharmaceutically acceptable excipient including a precipitating agent.